Tirzepatide for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 23 registered trials.

Why this status

  1. 3 Dec 2019: Trial registered, NCT04184622
  2. 4 Dec 2019: Trial started, NCT04184622
  3. 7 Dec 2020: Trial registered, NCT04657016
  4. 9 Dec 2020: Trial registered, NCT04660643
  5. 29 Mar 2021: Trial started, NCT04657016
  6. 29 Mar 2021: Trial started, NCT04660643
  7. 27 Aug 2021: Trial registered, NCT05024032
  8. 1 Sep 2021: Trial started, NCT05024032
  9. 27 Sep 2022: Trial registered, NCT05556512
  10. 11 Oct 2022: Trial started, NCT05556512
  11. 21 Apr 2023: Trial registered, NCT05822830
  12. 21 Apr 2023: Trial started, NCT05822830
  13. 20 Sep 2023: Trial started, NCT06047548
  14. 21 Sep 2023: Trial registered, NCT06047548
  15. 1 Jan 2025: Trial started, NCT06918405
  16. 6 Mar 2025: Trial started, NCT06864026
  17. 7 Mar 2025: Trial registered, NCT06864026
  18. 9 Apr 2025: Trial registered, NCT06918405
  19. 20 Oct 2025: Trial registered, NCT07218445
  20. 27 Feb 2026: Trial registered, NCT07438444
  21. 27 Feb 2026: Trial started, NCT07438444
  22. 8 Apr 2026: Trial started, NCT07218445
  23. 25 Jun 2026: Trial started, NCT07707778
  24. 16 Jul 2026: Trial registered, NCT07707778
  25. 16 Oct 2026: Trial started, NCT07881458
  26. 19 Oct 2026: Trial registered, NCT07881458

The trials

NCT04184622: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

State
Completed
Phase
Phase 3
People
2,539 taking part
Started
4 Dec 2019
Primary completion
1 Apr 2022
Arms
5 mg Tirzepatide, 10 mg Tirzepatide, 15 mg Tirzepatide
Results
Posted on the registry
  1. 3 Dec 2019: Trial registered
  2. 4 Dec 2019: Trial started
  3. 24 Apr 2023: Trial results posted
  4. 6 Jul 2024: Trial completed

NCT04311411: A Study of Tirzepatide in Overweight and Very Overweight Participants

State
Completed
Phase
Phase 1
People
114 taking part
Started
24 Aug 2020
Primary completion
16 Dec 2022
Arms
Tirzepatide
Results
Posted on the registry
  1. 17 Mar 2020: Trial registered
  2. 24 Aug 2020: Trial started
  3. 16 Dec 2022: Trial completed
  4. 22 May 2024: Trial results posted

NCT04657016: A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program

State
Completed
Phase
Phase 3
People
579 taking part
Started
29 Mar 2021
Primary completion
20 Apr 2023
Arms
Tirzepatide
Results
Posted on the registry
  1. 7 Dec 2020: Trial registered
  2. 29 Mar 2021: Trial started
  3. 12 May 2023: Trial completed
  4. 16 May 2024: Trial results posted

NCT04660643: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss

State
Completed
Phase
Phase 3
People
783 taking part
Started
29 Mar 2021
Primary completion
25 Apr 2023
Arms
Tirzepatide (lead-in), Tirzepatide MTD
Results
Posted on the registry
  1. 9 Dec 2020: Trial registered
  2. 29 Mar 2021: Trial started
  3. 18 May 2023: Trial completed
  4. 22 May 2024: Trial results posted

NCT05024032: A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

State
Completed
Phase
Phase 3
People
210 taking part
Started
1 Sep 2021
Primary completion
27 Dec 2022
Arms
10 Milligrams (mg) Tirzepatide, 15 mg Tirzepatide
Results
Posted on the registry
  1. 27 Aug 2021: Trial registered
  2. 1 Sep 2021: Trial started
  3. 27 Dec 2022: Trial completed
  4. 19 Jan 2024: Trial results posted

NCT05536804: A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

State
Completed
Phase
Phase 2
People
134 taking part
Started
8 Feb 2023
Primary completion
6 Jul 2026
Arms
Tirzepatide
Results
None posted
  1. 13 Sep 2022: Trial registered
  2. 8 Feb 2023: Trial started
  3. 30 Jul 2026: Trial completed

NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

State
Under way
Phase
Phase 3
People
15,374 taking part
Started
11 Oct 2022
Primary completion
Oct 2027
Arms
Tirzepatide
Results
None posted
  1. 27 Sep 2022: Trial registered
  2. 11 Oct 2022: Trial started

NCT05822830: A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities

State
Completed
Phase
Phase 3
People
751 taking part
Started
21 Apr 2023
Primary completion
13 Nov 2024
Arms
15 mg or MTD - Tirzepatide
Results
Posted on the registry
  1. 21 Apr 2023: Trial registered
  2. 21 Apr 2023: Trial started
  3. 13 Nov 2024: Trial completed
  4. 26 Nov 2025: Trial results posted

NCT06047548: A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

State
Completed
Phase
Phase 3
People
441 taking part
Started
20 Sep 2023
Primary completion
20 Jan 2026
Arms
Tirzepatide 5 milligram (mg), Tirzepatide Maximum Tolerated Dose
Results
None posted
  1. 20 Sep 2023: Trial started
  2. 21 Sep 2023: Trial registered
  3. 20 Jan 2026: Trial completed

NCT06297616: A Study of LY3841136 in Japanese Participants With Obesity or Overweight

State
Completed
Phase
Phase 1
People
128 taking part
Started
15 Apr 2024
Primary completion
21 Nov 2025
Arms
Part B: Tirzepatide + LY3841136-Placebo
Results
None posted
  1. 7 Mar 2024: Trial registered
  2. 15 Apr 2024: Trial started
  3. 21 Nov 2025: Trial completed

NCT06864026: A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

State
Under way
Phase
Phase 4
People
200 planned
Started
6 Mar 2025
Primary completion
Aug 2027
Arms
Tirzepatide
Results
None posted
  1. 6 Mar 2025: Trial started
  2. 7 Mar 2025: Trial registered

NCT06918405: Efficacy and Safety of Tirzepatide for Weight Management

State
Under way
Phase
Phase 3
People
440 planned
Started
1 Jan 2025
Primary completion
30 Jun 2026
Arms
Tirzepatide arm
Results
None posted
  1. 1 Jan 2025: Trial started
  2. 9 Apr 2025: Trial registered

NCT06994338: Tirzepatide for Alcohol Use Disorder

State
Under way
Phase
Phase 2
People
42 planned
Started
6 Oct 2025
Primary completion
31 Aug 2026
Arms
Tirzepatide
Results
None posted
  1. 29 May 2025: Trial registered
  2. 6 Oct 2025: Trial started

NCT07218445: The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity

State
Under way
Phase
Phase 4
People
40 planned
Started
8 Apr 2026
Primary completion
18 Sep 2027
Arms
Tirzepatide
Results
None posted
  1. 20 Oct 2025: Trial registered
  2. 8 Apr 2026: Trial started

NCT07292519: Tirzepatide Combined With Cognitive-Behavioural Therapy (CBT) for Adults With Alcohol Use Disorder (AUD) and Overweight/Obesity (OOB)

State
Not started
Phase
Phase 2
People
46 planned
Started
15 Jan 2026
Primary completion
15 May 2027
Arms
Tirzepatide: subcutaneous administration of Tirzepatide plus CBT ("Take Control" program)
Results
None posted
  1. 18 Dec 2025: Trial registered

NCT07364175: A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults

State
Under way
Phase
No phase
People
60 planned
Started
Jan 2026
Primary completion
Jan 2027
Arms
Tirzepatide [weight loss arm]
Results
None posted
  1. 23 Jan 2026: Trial registered

NCT07438444: A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

State
Under way
Phase
Phase 4
People
344 planned
Started
27 Feb 2026
Primary completion
Jul 2027
Arms
Tirzepatide
Results
None posted
  1. 27 Feb 2026: Trial registered
  2. 27 Feb 2026: Trial started

NCT07588438: Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.

State
Under way
Phase
Phase 4
People
160 planned
Started
27 Jul 2026
Primary completion
10 Aug 2027
Arms
Cohort 1: Obesity Without T2DM, Cohort 2: T2DM With or Without Obesity
Results
None posted
  1. 14 May 2026: Trial registered

NCT07707778: Tirzepatide's Effects on Epigenetic Aging and Metabolic Restoration in Virally Suppressed People With HIV

State
Under way
Phase
Phase 4
People
60 planned
Started
25 Jun 2026
Primary completion
Dec 2027
Arms
Interventional
Results
None posted
  1. 25 Jun 2026: Trial started
  2. 16 Jul 2026: Trial registered

NCT07738276: Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

State
Not started
Phase
Phase 3
People
60 planned
Started
18 Jul 2026
Primary completion
11 Jun 2027
Arms
Tirzepatide
Results
None posted
  1. 31 Jul 2026: Trial registered

NCT07829198: Efficacy of Tirzepatide for Weight Management in Patients With Suboptimal Weight Loss After Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

State
Not started
Phase
Phase 3
People
70 planned
Started
Jan 2027
Primary completion
Dec 2028
Arms
Tirzepatide
Results
None posted
  1. 18 Sep 2026: Trial registered

NCT07881432: A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes

State
Not started
Phase
Phase 3
People
2,115 planned
Started
Dec 2026
Primary completion
Oct 2029
Arms
Tirzepatide
Results
None posted
  1. 19 Oct 2026: Trial registered

NCT07881458: A Study of EloraTZP in Adult Participants With Obesity or Overweight and Type 2 Diabetes

State
Under way
Phase
Phase 3
People
1,000 planned
Started
16 Oct 2026
Primary completion
Oct 2029
Arms
Tirzepatide
Results
None posted
  1. 16 Oct 2026: Trial started
  2. 19 Oct 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Arm 5- Tirzepatide, Mounjaro, Tirzepatide (LIPOLESS de Laboratorio de Productos Eticos C.E.I.S.A.), Zepbound.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.